Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
10,96 USD | +3,35% | +1,82% | -2,89% |
05/04 | Arbutus Biopharma verkrijgt gunstig vonnis in rechtszaak over Moderna-patenten | MT |
04/04 | Moderna krijgt tegenslag in rechtszaak tegen Arbutus | MT |
Vakgebied
Aantal werknemers: 904
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 01-03-16 |
Richard Pulik
DFI | Director of Finance/CFO | - | 28-09-21 |
Eric Venker
PSD | President | 37 | 01-01-14 |
Mayukh Sukhatme
PSD | President | 48 | 01-01-15 |
Drew Kramer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Amy Mahery
PRN | Corporate Officer/Principal | - | 01-08-22 |
Kelly Graff
HRO | Human Resources Officer | - | 01-01-20 |
Jo Chen
LAW | General Counsel | - | 01-03-20 |
Srini Ramanathan
PRN | Corporate Officer/Principal | - | 02-05-22 |
Navneet Alag
PRN | Corporate Officer/Principal | - | 01-02-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 53 | 13-03-23 | |
Keith Manchester
BRD | Director/Board Member | 55 | 01-01-14 |
Dan Gold
BRD | Director/Board Member | 56 | 01-01-20 |
Melissa Epperly
BRD | Director/Board Member | 46 | 29-06-22 |
Mayukh Sukhatme
PSD | President | 48 | 01-01-15 |
Ilan Oren
CHM | Chairman | 40 | 01-01-14 |
Jim Momtazee
BRD | Director/Board Member | - | 01-10-21 |
Matthew Gline
CEO | Chief Executive Officer | 40 | 01-03-16 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 805 846 006 | 626 986 939 ( 77,80 %) | 0 | 77,80 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
IMMUNOVANT, INC. 54.93% | 79 805 331 | 54.93% | 2 578 510 245 $ |
38 847 462 | 21.64% | 100 226 452 $ |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,89% | 8,54 mld. | |
+27,15% | 659 mld. | |
+27,68% | 557 mld. | |
-4,32% | 359 mld. | |
+16,52% | 322 mld. | |
+9,78% | 297 mld. | |
+6,30% | 215 mld. | |
+4,80% | 210 mld. | |
-6,05% | 200 mld. | |
-8,81% | 149 mld. |
- Beurs
- Aandelen
- Koers ROIV
- Onderneming Roivant Sciences Ltd.